Sabrina Mahéo

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Marianne Weulersse, Assia Asrir, Andrea Pichler et al. · Immunity · 2020 · 139 citations · Full text

Life Sciences, Immunology, Oncology +14

TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation

Andrea Pichler, Nadège Carrié, Marine Cuisinier et al. · Immunity · 2023 · 111 citations · Full text

Life Sciences, Immunology, Oncology +17

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Céline Mazzotti, Laure Buisson, Sabrina Mahéo et al. · Blood Advances · 2018 · 90 citations · Full text

Medicine, Hematology, Oncology +16

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot et al. · Blood · 2022 · 62 citations · Full text

Medicine, Hematology, Oncology +8